Jean Tessier

First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors

Maria Martinez‐García, Udai Banerji, Joan Albanell et al. · Clinical Cancer Research · 2012 · 152 citations

Medicine, Oncology, Pharmacology +16

Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma

Alan Jackson, Gordon C. Jayson, K L Li et al. · British Journal of Radiology · 2003 · 134 citations

Medicine, Oncology, Radiology +15

Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours

D. Checkley, Jean Tessier, Jane Kendrew et al. · British Journal of Cancer · 2003 · 125 citations · Full text

Medicine, Oncology, Pharmacology +17

Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging

Simon P. Robinson, Dominick J. O. McIntyre, D. Checkley et al. · British Journal of Cancer · 2003 · 110 citations · Full text

Medicine, Oncology, Pharmacology +14

Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy

Benjamin Ribba, Christophe Boetsch, Tapan K. Nayak et al. · Clinical Cancer Research · 2018 · 81 citations · Full text

Pharmacy, Oncology, Pharmacokinetics +17